Linperlisib plus EZH2 inhibitor for relapsed PTCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a diagnosis of peripheral T-cell lymphoma (PTCL) — including certain subtypes like anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, or hepatosplenic T-cell lymphoma.
- You have already tried at least one standard treatment for your lymphoma. If you have anaplastic large cell lymphoma, you must have received a CD30-targeted therapy (like brentuximab vedotin).
- You have not been treated before with a PI3K inhibitor (like linperlisib) or an EZH2/EZH1/2 inhibitor.
- Your lymphoma can be measured on scans (at least one tumor that can be evaluated), and your overall health is good enough to be able to take care of yourself (ECOG score 0–2).
- Your organs (liver, kidneys, etc.) are working well, and you are expected to live at least 3 months.
- You are willing to use effective birth control during the study and for 6 months after your last dose, if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a combination of two drugs, linperlisib and chidamide, for people whose peripheral T-cell lymphoma has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or control the lymphoma.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.